Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age

Recruiting

Phase 3

Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age

Sponsor:

Vertex Pharmaceuticals Incorporated

Code:

NCT05882357

Conditions

Cystic Fibrosis

Eligibility Criteria

Sex: All

Age: 12 - 24

Healthy Volunteers: Not accepted

Interventions

ELX/TEZ/IVA

IVA

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information